1. US Partner: Competitor or Complementary
Player?
2. Single partner for several applications or
multiple partners per eac...
Contura Business Units
For urinary incontinence
Pipeline
New applications of soft tissue
filler technology
For facial augm...
2000: • Contura established
2001: • Aquamid®
granted the CE-marking for use in soft tissue facial augmentation
2003: • Bul...
Aesthetic Filler Market
Aquamid®
Positioning
Aquamid®
Pivotal Clinical Trial Results
Partnership Opportunity
US Aesthetics Filler Market
Total Aesthetics Medicine market size exceeds $13 Billion*
– Surgical procedures $ 8.4 B
– Non...
Market Dynamics: Many New Introductions
2004 2005 2006 2007 2008 2009
Radiesse Elevess
relaunch
Restylane Sculptra Juveder...
After cannibalizing Collagen, HA growth was blunted.
Number of procedures
0
200000
400000
600000
800000
1000000
1200000
14...
Competitive Players
Portfolio Approach in high gear
• Allergan: Botox + very successful launch of Juvederm line
• Mentor: ...
Aesthetic Filler Market
Aquamid®
Positioning
Aquamid®
Pivotal Clinical Trial Results
Partnership Opportunity
US Aesthetics Filler Market
Total Aesthetics Medicine market size exceeds $13 Billion*
– Surgical procedures $ 8.4 B
– Non...
Market Dynamics: Many New Introductions
2004 2005 2006 2007 2008 2009
Radiesse Elevess
relaunch
Restylane Sculptra Juveder...
After cannibalizing Collagen, HA growth was blunted.
Number of procedures
0
200000
400000
600000
800000
1000000
1200000
14...
Competitive Players
Portfolio Approach in high gear
• Allergan: Botox + very successful launch of Juvederm line
• Mentor: ...
Neurotoxin Collagen Hyaluronic
Acids
Longer
Lasting
Allergan YES YES YES
Medicis (Pipeline) YES
Mentor +
JnJ
(Pipeline) YE...
 Aquamid®
characteristics:
- Non-degradable
- Biocompatible, Non-migrational
- Non-allergenic, atoxic
- Homogeneous (no p...
Facial skin sags → Surgical Facelift
Loss of subcutaneous fat tissue → volume filler
“Boosting volume under the skin”
Wrin...
Unique Benefits of Aquamid®
Versatile volumizer: well suited for volumizing and sculpting procedures.
Directed to the subc...
 Naso labial folds
 Lip augmentation
 Cheek contouring
 Mento labial folds
 Glabella filling
 Nose correction
 Chin...
Durability of
augmentation
Compatibility
with tissue
Evolence
Soft Tissue Filler Positionings
Artefill
Sculptra Radiesse
J...
Aquamid®
Pivotal US Study Results
Study Design
Results Highlights
– Effectiveness
– Safety
Study Design
Aquamid®
– 210 subjects
Restylane®
– 105 subjects
Screening
Treatment
to Optimal
Max 3
sessions
3M 6M 9M 12M
...
Pivotal Study Key Conclusions
Successfully show that Aquamid®
is safe and effective for its intended use.
Support the regu...
Market Outlook
Flat to low growth through 1H 2009 due to economy and less DTC
advertising for next 6 months – however Boto...
Partnership Opportunity
Contura is seeking a US Marketing partner via a US/NA license to
commercialize Aquamid®
to its tar...
Other Potential Partners for Aquamid® Beyond
Current Filler Competitors
Therapeutic Dermatology Focus Aesthetic Equipment/...
Upcoming SlideShare
Loading in...5
×

1. US Partner: Competitor or Complementary Player?

427

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
427
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

1. US Partner: Competitor or Complementary Player?

  1. 1. 1. US Partner: Competitor or Complementary Player? 2. Single partner for several applications or multiple partners per each? 3. Funding options for research projects? PCCI January 19, 2009 Diana Mackie, Business Dev. Silvia G Codony, Clinical Research Contura International A/S (Archive Version)
  2. 2. Contura Business Units For urinary incontinence Pipeline New applications of soft tissue filler technology For facial augmentation Contura is a medical technology company based in Denmark focused on developing, manufacturing and commercializing soft tissue fillers that enhance the quality of people’s lives Contura is a medical technology company based in Denmark focused on developing, manufacturing and commercializing soft tissue fillers that enhance the quality of people’s lives
  3. 3. 2000: • Contura established 2001: • Aquamid® granted the CE-marking for use in soft tissue facial augmentation 2003: • Bulkamid® granted the CE-marking for use in the treatment of female urinary incontinence 2004: • Launch of Aquamid® Reconstruction for lipoatrophy, rhinoplasty and volume correction 2006: • FDA grants Aquamid® I D E, allowing its use in a major comparative clinical trial in the United States 2007: • Contura and ETHICON, a J & J company, sign agreement granting ETHICON exclusive worldwide distribution rights for Bulkamid® . • Contura’s United States subsidiary Contura Inc. established • Contura awarded the Product Differentiation Innovation Award for Aquamid® by Frost & Sullivan 2008: • Clinical trial of Bulkamid® in the United States begins • New manufacturing facility completed Contura History and Milestones
  4. 4. Aesthetic Filler Market Aquamid® Positioning Aquamid® Pivotal Clinical Trial Results Partnership Opportunity
  5. 5. US Aesthetics Filler Market Total Aesthetics Medicine market size exceeds $13 Billion* – Surgical procedures $ 8.4 B – Non-Surgical procedures $ 4.8 B Non-Surgical Procedures market size, includes MD fees & product – Botox > $ 1 B – All soft tissue fillers $ 1 B Number of Procedures – Botox 4.6 M $350 M at office retail – Soft Tissue Fillers 1.5 M $350 M at office retail * Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report
  6. 6. Market Dynamics: Many New Introductions 2004 2005 2006 2007 2008 2009 Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle ___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________► Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs) , Particle and Polymer brands (PPFs), Collagen brand
  7. 7. After cannibalizing Collagen, HA growth was blunted. Number of procedures 0 200000 400000 600000 800000 1000000 1200000 1400000 1600000 1800000 2003 2004 2005 2006 2007 Collagen Auto. Fat Hyaluronic Acid Radiesse Sculptra Artefill Source: ASAPS (ASPS data show same effect)
  8. 8. Competitive Players Portfolio Approach in high gear • Allergan: Botox + very successful launch of Juvederm line • Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J) • BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin) • Medicis: Neurotoxin + Restylane line • Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7) Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.
  9. 9. Aesthetic Filler Market Aquamid® Positioning Aquamid® Pivotal Clinical Trial Results Partnership Opportunity
  10. 10. US Aesthetics Filler Market Total Aesthetics Medicine market size exceeds $13 Billion* – Surgical procedures $ 8.4 B – Non-Surgical procedures $ 4.8 B Non-Surgical Procedures market size, includes MD fees & product – Botox > $ 1 B – All soft tissue fillers $ 1 B Number of Procedures – Botox 4.6 M $350 M at office retail – Soft Tissue Fillers 1.5 M $350 M at office retail * Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report
  11. 11. Market Dynamics: Many New Introductions 2004 2005 2006 2007 2008 2009 Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle ___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________► Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs) , Particle and Polymer brands (PPFs), Collagen brand
  12. 12. After cannibalizing Collagen, HA growth was blunted. Number of procedures 0 200000 400000 600000 800000 1000000 1200000 1400000 1600000 1800000 2003 2004 2005 2006 2007 Collagen Auto. Fat Hyaluronic Acid Radiesse Sculptra Artefill Source: ASAPS (ASPS data show same effect)
  13. 13. Competitive Players Portfolio Approach in high gear • Allergan: Botox + very successful launch of Juvederm line • Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J) • BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin) • Medicis: Neurotoxin + Restylane line • Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7) Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.
  14. 14. Neurotoxin Collagen Hyaluronic Acids Longer Lasting Allergan YES YES YES Medicis (Pipeline) YES Mentor + JnJ (Pipeline) YES YES BioForm Relaxed Expressions YES Artes Medical YES YES Each company started from one box and has been acquiring to complete the portfolio
  15. 15.  Aquamid® characteristics: - Non-degradable - Biocompatible, Non-migrational - Non-allergenic, atoxic - Homogeneous (no particles) - Exchanges water, salts and organic molecules with host tissue - Stored without refrigeration  Mode of Action -Volumizer – No intended foreign body reaction -full integration and vascularization Aquamid Has Unique Properties and Benefits  Aquamid® is an injectable hydrogel consisting of 97.5% water and 2.5% cross-linked polyacrylamide (1 ml syringe/27G needle)
  16. 16. Facial skin sags → Surgical Facelift Loss of subcutaneous fat tissue → volume filler “Boosting volume under the skin” Wrinkles & folds in lower face → dermal fillers Lines & wrinkles in upper face → neurotoxins A g e i n g Young Old New Trend: Volume Filling and Facial Sculpting
  17. 17. Unique Benefits of Aquamid® Versatile volumizer: well suited for volumizing and sculpting procedures. Directed to the subcutaneous tissue for immediate filling and lifting effect. Natural look and feel: The gel is homogeneous. Aquamid® does not induce inflammatory nodules or granulomas. Integrates completely with existing tissue. Lasting enhancement: non-resorbable and enduring augmentation. Clinical data demonstrate patient and investigator satisfaction that exceeds 90% after 5 years.
  18. 18.  Naso labial folds  Lip augmentation  Cheek contouring  Mento labial folds  Glabella filling  Nose correction  Chin augmentation  Scar correction  Facial augmentation to correct lipoatrophy  Minor body contouring Aquamid® Versatile in Applications
  19. 19. Durability of augmentation Compatibility with tissue Evolence Soft Tissue Filler Positionings Artefill Sculptra Radiesse Juvederm Restylane
  20. 20. Aquamid® Pivotal US Study Results Study Design Results Highlights – Effectiveness – Safety
  21. 21. Study Design Aquamid® – 210 subjects Restylane® – 105 subjects Screening Treatment to Optimal Max 3 sessions 3M 6M 9M 12M Treated area: nasolabial folds 13 Sites in the US – each with 19 - 33 subjects
  22. 22. Pivotal Study Key Conclusions Successfully show that Aquamid® is safe and effective for its intended use. Support the regulatory requirements for the PMA filing
  23. 23. Market Outlook Flat to low growth through 1H 2009 due to economy and less DTC advertising for next 6 months – however Botox grew by 13% in a challenging Q4/2008 New aesthetic medicines will launch, about one per year. Premium place given to those that leverage a sales force in place and where bundling can occur Aquamid® launch in 2010 should find an industry in growth again with receptive physicians and consumers.
  24. 24. Partnership Opportunity Contura is seeking a US Marketing partner via a US/NA license to commercialize Aquamid® to its target customers. The framework of a marketing plan is available and shows how Aquamid® would roll out to experienced and trained physicians in soft tissue fillers Aquamid® will sustain an appropriate price premium. Supply and further development to come from Contura A/S
  25. 25. Other Potential Partners for Aquamid® Beyond Current Filler Competitors Therapeutic Dermatology Focus Aesthetic Equipment/Device Focus Galderma Graceway American Laser Angiotech Pharma Merz Nycomed Cynosure New Star Lasers Obagi KIng PhotoMedex Syneron SkinMedica Stiefel Consumer Companies in OTC Derm Valeant P&G J&J DermaPlus DermaVance Schering-Plough Unilever
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×